Vyshak A. Venur

Vyshak A. Venur

Auto-generated profile, based on publicly available information

Vyshak A. Venur

Division of Medical Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
TGTyler Gutschenritter
Tyler Gutschenritter
VVVyshak A. Venur
Vyshak A. Venur
SCStephanie Combs
Stephanie Combs
BVBalamurugan Vellayappan
Balamurugan Vellayappan
APAnoop P. Patel
Anoop P. Patel
SLSimon Lo
Simon Lo
Brain metastases are the most common intracranial malignant tumor in adults and are a cause of significant morbidity and mortality for cancer patients. Large brain metastases, defined as tumors with a maximum dimension >2 cm, present a unique clinical challenge for the delivery of stereotactic radiosurgery (SRS) as patients often present with neurologic symptoms that require expeditious treatment that must also be balanced against the potential consequences of surgery and radiation therapy—namely, leptomeningeal disease (LMD) and radionecrosis (RN). Hypofractionated stereotactic radiotherapy (HSRT) and pre-operative SRS have emerged as novel treatment techniques to help improve local control rates and reduce rates of RN and LMD for this patient population commonly managed with post-operative SRS. Recent literature suggests that pre-operative SRS can potentially half the risk of LMD compared to post-operative SRS and that HSRT can improve risk of RN to less than 10% while improving local control when meeting the appropriate goals for biologically effective dose (BED) and dose-volume constraints. We recommend a 3- or 5-fraction regimen in lieu of SRS delivering 15 Gy or less for large metastases or resection cavities. We provide a table comparing the BED of commonly used SRS and HSRT regimens, and provide an algorithm to help guide the management of these challenging clinical scenarios.

29 November 2024 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
SSSasha N. Swensen
Sasha N. Swensen
KFKarl Cristie F. Figuracion
Karl Cristie F. Figuracion
VVVyshak A. Venur
Vyshak A. Venur
SESamuel Emerson
Samuel Emerson
YTYolanda D Tseng
Yolanda D Tseng
LHLia M. Halasz
Lia M. Halasz

31 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Zouina SarfrazZouina Sarfraz
Zouina Sarfraz
DJDiya Jayram
Diya Jayram
Ahmad OzairAhmad Ozair
Ahmad Ozair
LHLydia Hodgson
Lydia Hodgson
SBShreyas Bellur
Shreyas Bellur
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
Background: The development of brain metastases (BM) is a relatively uncommon but significantly adverse event in the spread of colorectal cancer (CRC). Although management of CRC BM has improved with advances in imaging and systemic therapies, clinical outcomes remain poor. Methods: This retrospective cohort study used the U.S. National Cancer Database to evaluate survival outcomes, treatment patterns, and prognostic factors in CRC patients diagnosed with BM between 2010 and 2020. Patients with isolated brain-only metastases formed the primary analytic cohort, while those with additional extracranial metastases were included for descriptive comparison. Multivariable Cox proportional hazards and logistic regression models were used to assess factors associated with of survival. Proportional hazards assumptions were tested using Schoenfeld residuals. Accelerated failure time models were also employed. Results: From a cohort of 1,040,877 individuals with CRC, 795 had metastatic disease present along with relevant data, of which 296 had isolated BM. Median overall survival (mOS) in BM-only metastatic disease group was 7.82 months (95% CI: 5.82–9.66). The longest survival was observed among patients treated with stereotactic radiosurgery combined with systemic therapy (SRS+Sys), with a median OS of 23.26 months (95% CI: 17.51–41.95) and a 3-year survival rate of 35.8%. In adjusted Cox models, SRS, systemic therapy, and definitive surgery of the primary site were each independently associated with reduced hazard of death. Rectal cancer patients had longer survival than those with colon primaries (mOS: 10.35 vs. 6.08 months). Age, comorbidity burden, and insurance status were not associated with survival in adjusted analyses. Conclusions: SRS+Sys was associated with longer survival compared to other treatment strategies. However, treatment selection is highly dependent on individual clinical factors such as performance status, comorbidities, and disease extent; therefore, these findings must be interpreted with caution Future prospective studies incorporating molecular and biomarker data are warranted to better guide care in this rare and high-risk group.

20 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TMTresa McGranahan
Tresa McGranahan
ABAlipi V. Bonm
Alipi V. Bonm
JSJennifer M. Specht
Jennifer M. Specht
VVVyshak Venur
Vyshak Venur
SLSimon Lo
Simon Lo
In the past 5 years, the treatment options available to patients with HER2+ breast cancer brain metastasis (BCBM) have expanded. The longer survival of patients with HER2+ BCBM renders understanding the toxicities of local therapies even more important to consider. After reviewing the available literature for HER2 targeted systemic therapies as well as local therapies, we present a simplified algorithm for when to prioritize systemic therapies over local therapies in patients with HER2+ BCBM.